Advanced Gastric Cancer Clinical Trial
Official title:
Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresctable Gastric Cancer
Verified date | November 2017 |
Source | Fuda Cancer Hospital, Guangzhou |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable gastric cancer.
Status | Completed |
Enrollment | 120 |
Est. completion date | November 30, 2018 |
Est. primary completion date | November 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: - All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies - Body tumor 1-6, with at least one tumor length > 2 cm - KPS = 70, lifespan:3-6 months - Platelet count = 80×109/L,white blood cell count = 3×109/L, neutrophil count = 2×109/L, hemoglobin = 80 g/L Exclusion Criteria: - Patients with cardiac pacemaker - Patients with brain metastasis - Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction |
Country | Name | City | State |
---|---|---|---|
China | Fuda cancer institute of Fuda cancer hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Fuda Cancer Hospital, Guangzhou | Shengxin Biotechnology Institute, Beijing |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relief degree of tumors | It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST) | 3 months | |
Secondary | Progress free survival(PFS) | The duration between treament and cancer recurrence | 1 year | |
Secondary | Overall survival | The duration between treament and patient pass way | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Completed |
NCT00821990 -
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01248403 -
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
|
Phase 3 | |
Not yet recruiting |
NCT01206218 -
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01851941 -
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
|
Phase 2 | |
Completed |
NCT00976768 -
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
|
Phase 2 | |
Active, not recruiting |
NCT03223376 -
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
|
Phase 3 | |
Completed |
NCT03609359 -
Lenvatinib and Pembrolizumab Simultaneous Combination Study
|
Phase 2 | |
Completed |
NCT02935634 -
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03579784 -
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
|
Phase 2 | |
Completed |
NCT02952729 -
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
|
Phase 1 | |
Recruiting |
NCT02072317 -
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
|
Phase 2 | |
Terminated |
NCT01402401 -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
|
Phase 2 | |
Completed |
NCT01503372 -
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT01472250 -
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|
N/A | |
Recruiting |
NCT01015339 -
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 3 | |
Completed |
NCT00842491 -
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT02071043 -
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
|
Phase 2 | |
Completed |
NCT01238055 -
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
|
Phase 2 |